Cargando…

A childhood-onset intestinal toxemia botulism during chemotherapy for relapsed acute leukemia

BACKGROUND: Botulism is a potentially fatal infection characterized by progressive muscle weakness, bulbar paralysis, constipation and other autonomic dysfunctions. A recent report suggested that cancer chemotherapy might increase the risk for the intestinal toxemia botulism in both adults and child...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohyama, Noriko, Torio, Michiko, Nakashima, Kentaro, Koga, Yuuki, Kanno, Shunsuke, Nishio, Hisanori, Nishiyama, Kei, Sasazuki, Momoko, Kato, Haru, Asakura, Hiroshi, Akamine, Satoshi, Sanefuji, Masafumi, Ishizaki, Yoshito, Sakai, Yasunari, Ohga, Shouichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604400/
https://www.ncbi.nlm.nih.gov/pubmed/28923072
http://dx.doi.org/10.1186/s12941-017-0240-y
Descripción
Sumario:BACKGROUND: Botulism is a potentially fatal infection characterized by progressive muscle weakness, bulbar paralysis, constipation and other autonomic dysfunctions. A recent report suggested that cancer chemotherapy might increase the risk for the intestinal toxemia botulism in both adults and children. CASE PRESENTATION: We report a 5-year-old boy, who developed general muscle weakness, constipation, ptosis and mydriasis during the third induction therapy for relapsed acute myeloid leukemia. He had recent histories of multiple antibiotic therapy for bacteremia and intake of well water at home. Repeated bacterial cultures identified Clostridium botulinum producing botulinum neurotoxin A. Botulinum toxin A was isolated from his stools at 17, 21, and 23 days after the onset. Symptoms were self-limiting, and were fully recovered without anti-botulinum toxin globulin therapy. CONCLUSION: This is the second report of a pediatric case with cancer chemotherapy-associated intestinal toxemia botulism. Our case provides further evidence that the immunocompromised status due to anti-cancer treatments increases the risk for the development of botulism at all ages in childhood.